Financial Survey: Zura Bio (NASDAQ:ZURA) and PharmaCyte Biotech (OTCMKTS:PMCBD)

PharmaCyte Biotech (OTCMKTS:PMCBD) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Institutional & Insider Ownership

0.0% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 15.8% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares PharmaCyte Biotech and Zura Bio’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A
Zura Bio	N/A	N/A	-$69.24 million	N/A	N/A

Profitability

This table compares PharmaCyte Biotech and Zura Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	-49.09%	-43.39%
Zura Bio	N/A	-28.83%	-22.91%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for PharmaCyte Biotech and Zura Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	N/A
Zura Bio	0	1	4	0	2.80

Zura Bio has a consensus target price of $15.50, suggesting a potential upside of 369.70%. Given Zura Bio’s higher possible upside, analysts clearly believe Zura Bio is more favorable than PharmaCyte Biotech.

Volatility & Risk

PharmaCyte Biotech has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500.

Summary

Zura Bio beats PharmaCyte Biotech on 6 of the 8 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.